Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.57 |
| ▸ | KIF11 | P52732 | 5/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4659812 | 0.94 | KIF11 (0.66) | KEAP1ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL3314859 | 0.88 | PGR (0.71) | KEAP1ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL12054668 | 0.87 | KEAP1 (0.75) | KEAP1ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL20491472 | 0.87 | NR3C2 (0.58) | KEAP1ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL21180504 | 0.85 | CA1 (0.49) | KEAP1ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL24732420 | 0.80 | CA1 (0.53) | ALDH1A1HPGDHTTCA1CA2 | |
| SCHEMBL31041151 | 0.80 | KIF11 (0.79) | KEAP1ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL20491464 | 0.79 | LMNA (0.51) | ALDH1A1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL20491390 | 0.79 | HPGD (0.51) | ALDH1A1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL21033855 | 0.78 | CA1 (0.52) | ALDH1A1HPGDHTTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| EP-3328843-B1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2022-10-26 | — | — | EP | disclosed |
| CN-107922362-B | 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2021-06-15 | — | — | CN | disclosed |
| WO-2021047674-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | 南京明德新药研发有限公司 | 2021-03-18 | — | — | WO | disclosed |
| WO-2020146657-A1 | PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-09-06 | — | — | US | disclosed |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1417169-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003016270-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| CN-1215392-A | Histamine H3 receptor ligands | BLACK JAMES FOUNDATION (GB) | 1999-04-28 | — | — | CN | disclosed |
| US-4766243-A | Electrophilic fluorination of aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1988-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | CYP3A5, CYP3A43, CYP3A4 | KEAP1 1391/4885ALDH1A1 850/4885SMN1; SMN2 1326/4885 |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | KEAP1 1006/4885ALDH1A1 1370/4885SMN1; SMN2 2653/4885 |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC6, HDAC2 | KEAP1 628/4885ALDH1A1 176/4885SMN1; SMN2 1602/4885 |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | KEAP1 1226/4885ALDH1A1 4261/4885SMN1; SMN2 2827/4885 |
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | MGAM, LCT, GANAB | KEAP1 593/4885ALDH1A1 315/4885SMN1; SMN2 3622/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | KEAP1 1006/4885ALDH1A1 1370/4885SMN1; SMN2 2653/4885 |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | CYP3A5, CYP3A43, CYP3A4 | KEAP1 1391/4885ALDH1A1 850/4885SMN1; SMN2 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.